Novavax (NVAX) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

After two years characterized by layoffs, pipeline reorganizations, FDA delays and clinical holds, Novavax CEO John Jacobs ...

Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell in December 2024? Novavax, Inc. (Nasdaq: NVAX), a global ...